Infectious Disease Experts Say Diagnostics Underutilized, More Needed
This article was originally published in The Gray Sheet
Executive Summary
The Infectious Diseases Society of America released a policy paper that “raises the red flag about the paucity of new and rapid tests despite years of promises from the molecular era.” It recommends simplifying regulations and improving the reimbursement process, as well as physician education.
You may also be interested in...
CMS Director To Diagnostics Industry: Prove Your Cancer Tests Work
“Why are insurers so reluctant to get enthusiastic and really embrace molecular diagnostics?” asked the director of CMS’ coverage and analysis group at a recent cancer diagnostics symposium. “Because half the time we have no idea what on earth we’re paying for.”
A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics
FDA’s much-anticipated guidance on expedited programs for drug development fills in some blanks on the new breakthrough designation, but simply advising sponsors they will need to pick up the pace on manufacturing plans and development of companion diagnostics leaves aspiring applicants wanting more, stakeholders said at DIA.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.